Kirk Look Biography and Net Worth

CFO of Oncolytics Biotech

Kirk Look is a Chartered Accountant with more than twenty years of experience in accounting, finance, tax and treasury. Mr. Look joined Oncolytics as the Company’s Controller in April 2003 and assumed the role of Chief Financial Officer in November 2012. Prior to joining Oncolytics, from 2000 to April 2003, Mr. Look was Manager of Audit and Assurance Services with Ernst & Young LLP in Canada. From 1998 to the end of 1999, Mr. Look held the positions of Audit Manager and Senior Accountant at Ernst & Young LLP in Chile. Mr. Look has a Bachelor of Commerce from the University of Calgary and a Master of Science in Jurisprudence Law Degree from the Seton Hall Law School.

What is Kirk Look's net worth?: The estimated net worth of Kirk Look is at least $146.88 thousand as of February 12th, 2026. Mr. Look owns 171,465 shares of Oncolytics Biotech stock worth more than $146,877 as of August 28th. This net worth estimate does not reflect any other investments that Mr. Look may own. Learn More about Kirk Look's net worth.
How do I contact Kirk Look?: The corporate mailing address for Mr. Look and other Oncolytics Biotech executives is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. Oncolytics Biotech can also be reached via phone at (403) 670-7377 and via email at [email protected]. Learn More on Kirk Look's contact information.
Has Kirk Look been buying or selling shares of Oncolytics Biotech?: Kirk Look has not been actively trading shares of Oncolytics Biotech within the last three months. Most recently, on Thursday, February 12th, Kirk Look bought 12,000 shares of Oncolytics Biotech stock. The stock was acquired at an average cost of $0.84 per share, with a total value of $10,080.00. Following the completion of the transaction, the chief financial officer now directly owns 287,515 shares of the company's stock, valued at $241,512.60. Learn More on Kirk Look's trading history.
Who are Oncolytics Biotech's active insiders?: Oncolytics Biotech's insider roster includes Andrew Aromando (Chief Business Officer), Deborah Brown (Director), Allison Hagerman (Chief Technology Officer), Jared Kelly (Chief Executive Officer & Director), Kirk Look (CFO), James Parsons (Director), and Bernd Seizinger (Director). Learn More on Oncolytics Biotech's active insiders.
Are insiders buying or selling shares of Oncolytics Biotech?: During the last year, Oncolytics Biotech insiders bought shares 14 times. They purchased a total of 404,282 shares worth more than $363,231.56. The most recent insider tranaction occured on March, 12th when CEO Jared Kelly bought 5,050 shares worth more than $4,848.00. Insiders at Oncolytics Biotech own 0.1% of the company. Learn More about insider trades at Oncolytics Biotech.
Information on this page was last updated on 3/12/2026.

Kirk Look Insider Trading History at Oncolytics Biotech

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
2/12/2026	Buy	12,000	$0.84	$10,080.00	287,515

Kirk Look Buying and Selling Activity at Oncolytics Biotech

Oncolytics Biotech Company Overview

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Today's Range

Now: $0.86

$0.82

$0.86

50 Day Range

MA: $0.85

$0.75

$0.96

2 Week Range

Now: $0.86

$0.73

$1.51

Volume

672,836 shs

Average Volume

1,275,661 shs

Market Capitalization

$109.23 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13